{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:43:58Z","timestamp":1792237438969,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1124\/jpet.122.001116","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T13:20:11Z","timestamp":1667136011000},"page":"173-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"384","author":[{"given":"Terry","family":"Podoll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allard","family":"Kaptein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Evarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerjan","family":"de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Emmelot-van Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"van Lith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Byard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Fretland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Hoogenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjeerd","family":"Barf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Greg","family":"Slatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001116_bib1","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1124\/jpet.122.001116_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/taap.2002.9440","article-title":"Drug metabolites in safety testing","volume":"182","author":"Baillie","year":"2002","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/jpet.122.001116_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): A covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001116_bib4","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm3003203","article-title":"Irreversible protein kinase inhibitors: balancing the benefits and risks","volume":"55","author":"Barf","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.122.001116_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/clpt.2013.81","article-title":"In vitro methods to support transporter evaluation in drug discovery and development","volume":"94","author":"Brouwer","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001116_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001116_bib7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/187231210792928206","article-title":"Reversible covalent binding of neratinib to human serum albumin in vitro","volume":"4","author":"Chandrasekaran","year":"2010","journal-title":"Drug Metab Lett"},{"key":"10.1124\/jpet.122.001116_bib8","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1111\/bcp.15278","article-title":"Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy","volume":"88","author":"Chen","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.122.001116_bib9","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.115.069203","article-title":"Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor","volume":"44","author":"Dickinson","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001116_bib10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.14988","article-title":"Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach","volume":"88","author":"Edlund","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.122.001116_bib11","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/bcp.15087","article-title":"Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies","volume":"88","author":"Edlund","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.122.001116_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40262-018-0725-7","article-title":"Population pharmacokinetics of the BTK inhibitor acalabrutinib and its active metabolite in healthy volunteers and patients with B-cell malignancies","volume":"58","author":"Edlund","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.122.001116_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1124\/jpet.122.001116_bib14","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.122.001116_bib15","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The Bruton Tyrosine Kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia","volume":"23","author":"Herman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1124\/jpet.122.001116_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-015-0346-3","article-title":"The effect of famotidine, a MATE1-selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin","volume":"55","author":"Hibma","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.122.001116_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.119.262063","article-title":"Relative selectivity of covalent inhibitors requires assessment of inactivation kinetics and cellular occupancy: a case study of ibrutinib and acalabrutinib","volume":"372","author":"Hopper","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001116_bib18","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0022-3565(24)35013-X","article-title":"Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation","volume":"290","author":"Jones","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 1","key":"10.1124\/jpet.122.001116_bib19","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-99-109973","article-title":"Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies [poster]","volume":"132","author":"Kaptein","year":"2018","journal-title":"Blood"},{"key":"10.1124\/jpet.122.001116_bib20","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1124\/dmd.118.081729","article-title":"An assessment of the in vitro inhibition of cytochrome P450 enzymes, UDP-glucuronosyltransferases, and transporters by phosphodiester- or phosphorothioate-linked oligonucleotides","volume":"46","author":"Kazmi","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001116_bib21","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/S0021-9258(18)50153-8","article-title":"Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase","volume":"237","author":"Kitz","year":"1962","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.122.001116_bib22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1177\/1087057109336751","article-title":"Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values","volume":"14","author":"Krippendorff","year":"2009","journal-title":"J Biomol Screen"},{"key":"10.1124\/jpet.122.001116_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem Biol"},{"key":"10.1124\/jpet.122.001116_bib24","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1039\/C7CS00220C","article-title":"Structure-based design of targeted covalent inhibitors","volume":"47","author":"Lonsdale","year":"2018","journal-title":"Chem Soc Rev"},{"key":"10.1124\/jpet.122.001116_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1124\/jpet.122.001116_bib26","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.109.028274","article-title":"In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran","volume":"37","author":"Paris","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001116_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/dmd.118.084459","article-title":"Bioavailability, biotransformation, and excretion of the covalent Bruton tyrosine kinase inhibitor acalabrutinib in rats, dogs, and humans","volume":"47","author":"Podoll","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001116_bib28","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton\u2019s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.122.001116_bib29","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0090-9556(24)15146-X","article-title":"In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil","volume":"28","author":"Robertson","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001116_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.114.060061","article-title":"Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men","volume":"43","author":"Scheers","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"10.1124\/jpet.122.001116_bib31","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2021-148544","article-title":"Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (pts) with relapsed\/refractory B-cell malignancies (Abstract 1410)","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood"},{"key":"10.1124\/jpet.122.001116_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.122.001116_bib33","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.122.001116_bib34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12154-009-0023-9","article-title":"Measuring and interpreting the selectivity of protein kinase inhibitors","volume":"2","author":"Smyth","year":"2009","journal-title":"J Chem Biol"},{"key":"10.1124\/jpet.122.001116_bib35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00280-011-1803-9","article-title":"Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers","volume":"69","author":"Stopfer","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/jpet.122.001116_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1087057116671509","article-title":"A perspective on the kinetics of covalent and irreversible inhibition","volume":"22","author":"Strelow","year":"2017","journal-title":"SLAS Discov"},{"key":"10.1124\/jpet.122.001116_bib37","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1124\/dmd.107.015016","article-title":"Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process","volume":"35","author":"Watanabe","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.122.001116_bib38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cpt.1082","article-title":"ITC commentary on metformin clinical drug-drug interaction study design that enables an efficacy- and safety-based dose adjustment decision","volume":"104","author":"Zamek-Gliszczynski","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.122.001116_bib39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/psp4.12408","article-title":"Evaluation of the drug-drug interaction potential of acalabrutinib and its active metabolite, ACP-5862, using a physiologically-based pharmacokinetic modeling approach","volume":"8","author":"Zhou","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524003847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T16:50:47Z","timestamp":1740675047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524003847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0022356524003847"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001116","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The Author(s)","name":"copyright","label":"Copyright"}]}}